Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PVLA vs GLPG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GLPG Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–2 Matrix Metrics)

GLPG Overall Winner 6-Pillar Tally: PVLA 1 – 4 GLPG (1 Tie) Matrix Metrics: PVLA 2 – 7 GLPG

As of Nov 16, 2026, Galapagos NV (GLPG) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas GLPG carries 61.5/100 (BUY) at $27.73 (N/M Forward P/E, 88.0% operating margin).

  • Technical & Structure Timing Caution: PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9); meanwhile GLPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PVLA vs GLPG
PVLA NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.9 · SMA20: $148.17 · SMA50: $143.42
GLPG NASDAQ Head-to-Head Winner
Galapagos NV
Pharmaceutical Preparations
$27.73
-3.75% 1D
Market Cap $1.9B
TTM Revenue $602M
Forward P/E N/M
Beta / 30D Vol 0.71β · 20% Vol
Unified Composite Score
61.5 / 100 BUY
Tech 45.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.7%), weak momentum, RSI 36
RSI-14: 36.5 · SMA20: $28.59 · SMA50: $30.32

6-Pillar Scorecard Institutional Category Breakdown (PVLA 1 – 4 GLPG)

Columns: Metric · PVLA · GLPG
1. Valuation Multiples GLPG
Forward P/E N/M N/M
Trailing P/E N/M 5.1x
PEG Ratio N/M N/M
EV / Revenue N/M 3.2x
2. Growth & Scale GLPG
Revenue Growth (YoY) +0.0% +1093.2%
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A $602M
Market Cap $2.2B $1.9B
3. Profitability & Quality GLPG
Gross Margin N/A 56.0%
Operating Margin 0.0% 88.0%
Net Profit Margin 0.0% 28.8%
Return on Equity (ROE) -63.4% 10.4%
4. Balance Sheet & Cash Flow GLPG
Cash Generation (TTM) -$43M $308M EBITDA
Cash Flow Margin N/A 51.1% EBITDA Mgn
Net Cash / Leverage $193M Net Cash $2.90 Book/Sh · 10.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PVLA
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 47.9% (2nd %ile) 35.2% (2nd %ile)
Put/Call OI Skew 3.82x (Put-Skewed) Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PVLA (2) vs GLPG (7)
Institutional Metric PVLA GLPG Criterion Row Edge
Market Capitalization
Scale
$2.2B $1.9B Larger Scale PVLA
Trailing P/E Ratio
Valuation
N/M 5.1x Lower Multiple GLPG
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +1093.2% Higher Growth GLPG
Operating Margin (TTM)
Profitability
0.0% 88.0% Higher Margin GLPG
Net Profit Margin
Profitability
0.0% 28.8% Higher Margin GLPG
Return on Equity (ROE)
Capital Efficiency
-63.4% 10.4% Higher ROE GLPG
52-Week Range Position
Momentum
68% ($72–$180) 23% ($25–$38) Stronger Trend PVLA
Beta / 30D Volatility
Risk Regime
1.66β · 75% Vol 0.71β · 20% Vol Lower Realized Risk GLPG
Unified Institutional Score
Composite Signal
48.2 / 100 (HOLD) 61.5 / 100 (BUY) Higher Composite GLPG
Trailing 12M Revenue (USD)
Operating Scale
N/A $602M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 56.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$43M ($193M Net Cash) $308M EBITDA ($2.90 Book/Sh · 10.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GLPG +4.03 pp
PVLA: -8.05% · GLPG: -4.02%
3M Horizon PVLA +65.12 pp
PVLA: +48.19% · GLPG: -16.93%
6M Horizon PVLA +52.64 pp
PVLA: +40.7% · GLPG: -11.94%
1Y Horizon PVLA +52.64 pp
PVLA: +40.7% · GLPG: -11.94%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PVLA vs GLPG. Trailing 12-month operating profitability (PVLA 0.0% vs GLPG 88.0%) and valuation multiples (PVLA N/M vs GLPG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PVLA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-63.4% · N/M
GLPG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$602M
Gross Margin56.0%
Op. Margin88.0%
ROE / Fwd P/E10.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GLPG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 35.2%
IV Percentile 2nd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GLPG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GLPG Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and 88.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PVLA vs GLPG Key Questions & Quantitative Answers

As of Nov 16, 2026, Galapagos NV (GLPG) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas GLPG carries 61.5/100 (BUY) at $27.73 (N/M Forward P/E, 88.0% operating margin). Technical & Structure Timing Caution: PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9); meanwhile GLPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GLPG leads the Growth & Scale pillar: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with GLPG at +1093.2% YoY revenue growth and N/A YoY earnings growth on $602M TTM revenue (56.0% gross margin, 88.0% operating margin). On trailing 12-month operating scale, PVLA generates N/A in USD-normalized revenue versus $602M for GLPG. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GLPG.

GLPG screens cheaper on headline valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas GLPG trades at N/M Forward P/E, 5.1x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (51.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus GLPG (10.4% ROE) capital efficiency.

In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, GLPG carries 35.2% implied volatility (2nd %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 20% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.